25 XP   0   0   10

Ascletis Pharma Inc
Buy, Hold or Sell?

Let's analyse Ascletis together

PenkeI guess you are interested in Ascletis Pharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Ascletis Pharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Ascletis Pharma Inc

I send you an email if I find something interesting about Ascletis Pharma Inc.

Quick analysis of Ascletis (30 sec.)










What can you expect buying and holding a share of Ascletis? (30 sec.)

How much money do you get?

How much money do you get?
HK$0.00
When do you have the money?
1 year
How often do you get paid?
42.9%

What is your share worth?

Current worth
HK$2.53
Expected worth in 1 year
HK$1.77
How sure are you?
42.9%

+ What do you gain per year?

Total Gains per Share
HK$-0.76
Return On Investment
-53.7%

For what price can you sell your share?

Current Price per Share
HK$1.41
Expected price per share
HK$1.24 - HK$1.93
How sure are you?
50%

1. Valuation of Ascletis (5 min.)




Live pricePrice per Share (EOD)

HK$1.41

Intrinsic Value Per Share

HK$-1.75 - HK$-0.54

Total Value Per Share

HK$0.78 - HK$1.99

2. Growth of Ascletis (5 min.)




Is Ascletis growing?

Current yearPrevious yearGrowGrow %
How rich?$351.2m$377.4m-$26.1m-7.4%

How much money is Ascletis making?

Current yearPrevious yearGrowGrow %
Making money-$43.5m-$27.5m-$16m-36.8%
Net Profit Margin-582.1%-258.9%--

How much money comes from the company's main activities?

3. Financial Health of Ascletis (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#159 / 1031

Most Revenue
#319 / 1031

Most Profit
#902 / 1031

Most Efficient
#775 / 1031

What can you expect buying and holding a share of Ascletis? (5 min.)

Welcome investor! Ascletis's management wants to use your money to grow the business. In return you get a share of Ascletis.

What can you expect buying and holding a share of Ascletis?

First you should know what it really means to hold a share of Ascletis. And how you can make/lose money.

Speculation

The Price per Share of Ascletis is HK$1.41. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Ascletis.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Ascletis, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is HK$2.53. Based on the TTM, the Book Value Change Per Share is HK$-0.19 per quarter. Based on the YOY, the Book Value Change Per Share is HK$-0.21 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is HK$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Ascletis.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 HK$% of Price per ShareHK$% of Price per ShareHK$% of Price per ShareHK$% of Price per ShareHK$% of Price per Share
Usd Eps-0.04-2.8%-0.04-2.8%-0.03-1.8%-0.02-1.5%-0.02-1.2%
Usd Book Value Change Per Share-0.02-1.7%-0.02-1.7%-0.03-1.9%0.043.1%0.053.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.1%0.000.2%
Usd Total Gains Per Share-0.02-1.7%-0.02-1.7%-0.03-1.9%0.043.2%0.053.5%
Usd Price Per Share0.61-0.61-0.42-0.52-0.37-
Price to Earnings Ratio-15.13--15.13--16.60--197.25--140.90-
Price-to-Total Gains Ratio-25.04--25.04--15.38--19.61--19.61-
Price to Book Ratio1.87-1.87-1.21-1.38-0.99-
Price-to-Total Gains Ratio-25.04--25.04--15.38--19.61--19.61-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.180198
Number of shares5549
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.020.04
Usd Total Gains Per Share-0.020.04
Gains per Quarter (5549 shares)-134.25247.37
Gains per Year (5549 shares)-537.01989.46
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-537-54732958979
20-1074-10846319161968
30-1611-16219528732957
40-2148-215812738313946
50-2685-269515847894935
60-3222-323219057475924
70-3759-376922267056913
80-4296-430625376627902
90-4833-484328586208891
100-5370-538031795789880

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.07.00.00.0%0.07.00.00.0%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%3.04.00.042.9%3.04.00.042.9%
Dividend per Share0.00.01.00.0%0.00.03.00.0%1.00.04.020.0%3.00.04.042.9%3.00.04.042.9%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%3.04.00.042.9%3.04.00.042.9%

Fundamentals of Ascletis

About Ascletis Pharma Inc

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB); ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.

Fundamental data was last updated by Penke on 2024-03-25 10:19:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Ascletis Pharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Ascletis earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Ascletis to the Biotechnology industry mean.
  • A Net Profit Margin of -582.1% means that $-5.82 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Ascletis Pharma Inc:

  • The MRQ is -582.1%. The company is making a huge loss. -2
  • The TTM is -582.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-582.1%TTM-582.1%0.0%
TTM-582.1%YOY-258.9%-323.2%
TTM-582.1%5Y-299.7%-282.4%
5Y-299.7%10Y-240.2%-59.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-582.1%-171.8%-410.3%
TTM-582.1%-205.8%-376.3%
YOY-258.9%-262.1%+3.2%
5Y-299.7%-455.6%+155.9%
10Y-240.2%-589.0%+348.8%
1.1.2. Return on Assets

Shows how efficient Ascletis is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Ascletis to the Biotechnology industry mean.
  • -11.8% Return on Assets means that Ascletis generated $-0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Ascletis Pharma Inc:

  • The MRQ is -11.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.8%TTM-11.8%0.0%
TTM-11.8%YOY-7.0%-4.8%
TTM-11.8%5Y-5.7%-6.1%
5Y-5.7%10Y-5.6%-0.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.8%-12.5%+0.7%
TTM-11.8%-12.2%+0.4%
YOY-7.0%-11.2%+4.2%
5Y-5.7%-13.4%+7.7%
10Y-5.6%-14.7%+9.1%
1.1.3. Return on Equity

Shows how efficient Ascletis is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Ascletis to the Biotechnology industry mean.
  • -12.4% Return on Equity means Ascletis generated $-0.12 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Ascletis Pharma Inc:

  • The MRQ is -12.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -12.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.4%TTM-12.4%0.0%
TTM-12.4%YOY-7.3%-5.1%
TTM-12.4%5Y-6.0%-6.4%
5Y-6.0%10Y-7.0%+1.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.4%-15.8%+3.4%
TTM-12.4%-15.7%+3.3%
YOY-7.3%-13.9%+6.6%
5Y-6.0%-18.3%+12.3%
10Y-7.0%-19.2%+12.2%

1.2. Operating Efficiency of Ascletis Pharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Ascletis is operating .

  • Measures how much profit Ascletis makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Ascletis to the Biotechnology industry mean.
  • An Operating Margin of -644.5% means the company generated $-6.45  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Ascletis Pharma Inc:

  • The MRQ is -644.5%. The company is operating very inefficient. -2
  • The TTM is -644.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-644.5%TTM-644.5%0.0%
TTM-644.5%YOY-299.8%-344.7%
TTM-644.5%5Y-295.3%-349.3%
5Y-295.3%10Y-247.5%-47.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-644.5%-299.1%-345.4%
TTM-644.5%-210.1%-434.4%
YOY-299.8%-279.7%-20.1%
5Y-295.3%-459.9%+164.6%
10Y-247.5%-596.9%+349.4%
1.2.2. Operating Ratio

Measures how efficient Ascletis is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 8.74 means that the operating costs are $8.74 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Ascletis Pharma Inc:

  • The MRQ is 8.735. The company is inefficient in keeping operating costs low. -1
  • The TTM is 8.735. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ8.735TTM8.7350.000
TTM8.735YOY3.885+4.850
TTM8.7355Y4.522+4.213
5Y4.52210Y3.882+0.641
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.7352.861+5.874
TTM8.7353.193+5.542
YOY3.8853.615+0.270
5Y4.5225.560-1.038
10Y3.8827.396-3.514

1.3. Liquidity of Ascletis Pharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Ascletis is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 23.52 means the company has $23.52 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Ascletis Pharma Inc:

  • The MRQ is 23.521. The company is very able to pay all its short-term debts. +2
  • The TTM is 23.521. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ23.521TTM23.5210.000
TTM23.521YOY28.927-5.406
TTM23.5215Y32.648-9.127
5Y32.64810Y25.488+7.160
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ23.5213.986+19.535
TTM23.5214.440+19.081
YOY28.9275.552+23.375
5Y32.6486.158+26.490
10Y25.4886.492+18.996
1.3.2. Quick Ratio

Measures if Ascletis is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Ascletis to the Biotechnology industry mean.
  • A Quick Ratio of 0.32 means the company can pay off $0.32 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Ascletis Pharma Inc:

  • The MRQ is 0.324. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.324. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.324TTM0.3240.000
TTM0.324YOY28.135-27.811
TTM0.3245Y41.609-41.285
5Y41.60910Y31.924+9.685
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3243.638-3.314
TTM0.3244.168-3.844
YOY28.1355.515+22.620
5Y41.6096.012+35.597
10Y31.9246.209+25.715

1.4. Solvency of Ascletis Pharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Ascletis assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Ascletis to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.04 means that Ascletis assets are financed with 4.4% credit (debt) and the remaining percentage (100% - 4.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Ascletis Pharma Inc:

  • The MRQ is 0.044. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.044. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.044TTM0.0440.000
TTM0.044YOY0.036+0.008
TTM0.0445Y0.033+0.011
5Y0.03310Y0.075-0.042
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0440.335-0.291
TTM0.0440.330-0.286
YOY0.0360.267-0.231
5Y0.0330.367-0.334
10Y0.0750.378-0.303
1.4.2. Debt to Equity Ratio

Measures if Ascletis is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Ascletis to the Biotechnology industry mean.
  • A Debt to Equity ratio of 4.6% means that company has $0.05 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Ascletis Pharma Inc:

  • The MRQ is 0.046. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.046. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.046TTM0.0460.000
TTM0.046YOY0.037+0.009
TTM0.0465Y0.034+0.012
5Y0.03410Y0.120-0.086
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0460.376-0.330
TTM0.0460.398-0.352
YOY0.0370.334-0.297
5Y0.0340.429-0.395
10Y0.1200.476-0.356

2. Market Valuation of Ascletis Pharma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Ascletis generates.

  • Above 15 is considered overpriced but always compare Ascletis to the Biotechnology industry mean.
  • A PE ratio of -15.13 means the investor is paying $-15.13 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Ascletis Pharma Inc:

  • The EOD is -4.499. Based on the earnings, the company is expensive. -2
  • The MRQ is -15.125. Based on the earnings, the company is expensive. -2
  • The TTM is -15.125. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.499MRQ-15.125+10.626
MRQ-15.125TTM-15.1250.000
TTM-15.125YOY-16.602+1.477
TTM-15.1255Y-197.253+182.128
5Y-197.25310Y-140.895-56.358
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.499-2.643-1.856
MRQ-15.125-2.418-12.707
TTM-15.125-2.742-12.383
YOY-16.602-4.123-12.479
5Y-197.253-6.257-190.996
10Y-140.895-6.478-134.417
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Ascletis Pharma Inc:

  • The EOD is -9.031. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -30.360. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -30.360. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.031MRQ-30.360+21.329
MRQ-30.360TTM-30.3600.000
TTM-30.360YOY-21.437-8.922
TTM-30.3605Y-29.415-0.945
5Y-29.41510Y-21.011-8.404
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-9.031-3.244-5.787
MRQ-30.360-2.939-27.421
TTM-30.360-3.478-26.882
YOY-21.437-5.592-15.845
5Y-29.415-8.473-20.942
10Y-21.011-8.881-12.130
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Ascletis is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.87 means the investor is paying $1.87 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Ascletis Pharma Inc:

  • The EOD is 0.558. Based on the equity, the company is cheap. +2
  • The MRQ is 1.875. Based on the equity, the company is underpriced. +1
  • The TTM is 1.875. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.558MRQ1.875-1.317
MRQ1.875TTM1.8750.000
TTM1.875YOY1.211+0.664
TTM1.8755Y1.381+0.494
5Y1.38110Y0.986+0.394
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.5582.124-1.566
MRQ1.8752.041-0.166
TTM1.8752.118-0.243
YOY1.2112.915-1.704
5Y1.3813.682-2.301
10Y0.9864.114-3.128
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Ascletis Pharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.189-0.1890%-0.214+13%0.338-156%0.361-152%
Book Value Per Share--2.5282.5280%2.717-7%2.948-14%2.282+11%
Current Ratio--23.52123.5210%28.927-19%32.648-28%25.488-8%
Debt To Asset Ratio--0.0440.0440%0.036+24%0.033+33%0.075-41%
Debt To Equity Ratio--0.0460.0460%0.037+25%0.034+34%0.120-62%
Dividend Per Share----0%-0%0.011-100%0.025-100%
Eps---0.313-0.3130%-0.198-37%-0.164-48%-0.128-59%
Free Cash Flow Per Share---0.156-0.1560%-0.153-2%-0.137-13%-0.138-12%
Free Cash Flow To Equity Per Share---0.158-0.1580%-0.184+17%0.338-147%0.289-155%
Gross Profit Margin--1.0001.0000%1.0000%2.851-65%2.322-57%
Intrinsic Value_10Y_max---0.539--------
Intrinsic Value_10Y_min---1.746--------
Intrinsic Value_1Y_max---0.119--------
Intrinsic Value_1Y_min---0.153--------
Intrinsic Value_3Y_max---0.308--------
Intrinsic Value_3Y_min---0.482--------
Intrinsic Value_5Y_max---0.437--------
Intrinsic Value_5Y_min---0.832--------
Market Cap1427991600.000-261%5153015160.0005153015160.0000%3575354860.000+44%4462370266.000+15%3187407332.857+62%
Net Profit Margin---5.821-5.8210%-2.589-56%-2.997-49%-2.402-59%
Operating Margin---6.445-6.4450%-2.998-53%-2.953-54%-2.475-62%
Operating Ratio--8.7358.7350%3.885+125%4.522+93%3.882+125%
Pb Ratio0.558-236%1.8751.8750%1.211+55%1.381+36%0.986+90%
Pe Ratio-4.499+70%-15.125-15.1250%-16.602+10%-197.253+1204%-140.895+832%
Price Per Share1.410-236%4.7404.7400%3.290+44%4.048+17%2.891+64%
Price To Free Cash Flow Ratio-9.031+70%-30.360-30.3600%-21.437-29%-29.415-3%-21.011-31%
Price To Total Gains Ratio-7.448+70%-25.038-25.0380%-15.379-39%-19.612-22%-19.612-22%
Quick Ratio--0.3240.3240%28.135-99%41.609-99%31.924-99%
Return On Assets---0.118-0.1180%-0.070-41%-0.057-52%-0.056-53%
Return On Equity---0.124-0.1240%-0.073-41%-0.060-52%-0.070-44%
Total Gains Per Share---0.189-0.1890%-0.214+13%0.349-154%0.386-149%
Usd Book Value--351246879.869351246879.8690%377409862.071-7%414939012.011-15%321651322.746+9%
Usd Book Value Change Per Share---0.024-0.0240%-0.027+13%0.043-156%0.046-152%
Usd Book Value Per Share--0.3230.3230%0.347-7%0.377-14%0.292+11%
Usd Dividend Per Share----0%-0%0.001-100%0.003-100%
Usd Eps---0.040-0.0400%-0.025-37%-0.021-48%-0.016-59%
Usd Free Cash Flow---21691712.973-21691712.9730%-21314727.945-2%-19197748.192-11%-19463842.487-10%
Usd Free Cash Flow Per Share---0.020-0.0200%-0.020-2%-0.017-13%-0.018-12%
Usd Free Cash Flow To Equity Per Share---0.020-0.0200%-0.024+17%0.043-147%0.037-155%
Usd Market Cap182497326.480-261%658555337.448658555337.4480%456930351.108+44%570290919.995+15%407350657.139+62%
Usd Price Per Share0.180-236%0.6060.6060%0.420+44%0.517+17%0.370+64%
Usd Profit---43540387.796-43540387.7960%-27522534.590-37%-22854973.156-48%-17920124.161-59%
Usd Revenue--7480234.8347480234.8340%10631365.005-30%13987859.360-47%11693865.360-36%
Usd Total Gains Per Share---0.024-0.0240%-0.027+13%0.045-154%0.049-149%
 EOD+3 -5MRQTTM+0 -0YOY+10 -235Y+4 -3210Y+9 -27

3.2. Fundamental Score

Let's check the fundamental score of Ascletis Pharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.499
Price to Book Ratio (EOD)Between0-10.558
Net Profit Margin (MRQ)Greater than0-5.821
Operating Margin (MRQ)Greater than0-6.445
Quick Ratio (MRQ)Greater than10.324
Current Ratio (MRQ)Greater than123.521
Debt to Asset Ratio (MRQ)Less than10.044
Debt to Equity Ratio (MRQ)Less than10.046
Return on Equity (MRQ)Greater than0.15-0.124
Return on Assets (MRQ)Greater than0.05-0.118
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Ascletis Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5030.056
Ma 20Greater thanMa 501.614
Ma 50Greater thanMa 1001.671
Ma 100Greater thanMa 2001.682
OpenGreater thanClose1.500
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets2,657,042
Total Liabilities117,156
Total Stockholder Equity2,539,886
 As reported
Total Liabilities 117,156
Total Stockholder Equity+ 2,539,886
Total Assets = 2,657,042

Assets

Total Assets2,657,042
Total Current Assets2,544,726
Long-term Assets112,316
Total Current Assets
Cash And Cash Equivalents 2,470,834
Short-term Investments 11,200
Net Receivables 23,873
Inventory 20,519
Other Current Assets 8,125
Total Current Assets  (as reported)2,544,726
Total Current Assets  (calculated)2,534,551
+/- 10,175
Long-term Assets
Property Plant Equipment 73,041
Intangible Assets 16,559
Other Assets 1,913
Long-term Assets  (as reported)112,316
Long-term Assets  (calculated)91,513
+/- 20,803

Liabilities & Shareholders' Equity

Total Current Liabilities108,189
Long-term Liabilities8,967
Total Stockholder Equity2,539,886
Total Current Liabilities
Accounts payable 3,135
Other Current Liabilities 46,487
Total Current Liabilities  (as reported)108,189
Total Current Liabilities  (calculated)49,622
+/- 58,567
Long-term Liabilities
Other Liabilities 7,146
Deferred Long Term Liability 698
Long-term Liabilities  (as reported)8,967
Long-term Liabilities  (calculated)7,844
+/- 1,123
Total Stockholder Equity
Common Stock742
Other Stockholders Equity 702,001
Total Stockholder Equity (as reported)2,539,886
Total Stockholder Equity (calculated)702,743
+/- 1,837,143
Other
Capital Stock742
Common Stock Shares Outstanding 1,087,134
Net Invested Capital 2,539,886
Net Tangible Assets 2,523,327
Net Working Capital 2,436,537
Property Plant and Equipment Gross 130,342



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
> Total Assets 
536,265
991,254
3,527,603
3,426,387
3,067,072
2,829,959
2,657,042
2,657,0422,829,9593,067,0723,426,3873,527,603991,254536,265
   > Total Current Assets 
466,008
875,618
3,363,336
3,192,574
2,829,987
2,631,551
2,544,726
2,544,7262,631,5512,829,9873,192,5743,363,336875,618466,008
       Cash And Cash Equivalents 
418,973
607,367
3,173,249
2,989,164
2,714,011
2,495,496
2,470,834
2,470,8342,495,4962,714,0112,989,1643,173,249607,367418,973
       Short-term Investments 
5,610
143,831
1,871,781
2,821,182
1,457,744
5,200
11,200
11,2005,2001,457,7442,821,1821,871,781143,8315,610
       Net Receivables 
17,694
29,634
86,201
101,649
48,227
53,606
23,873
23,87353,60648,227101,64986,20129,63417,694
       Inventory 
18,747
62,211
83,877
86,039
58,894
56,233
20,519
20,51956,23358,89486,03983,87762,21118,747
       Other Current Assets 
3,189
26,527
15,084
9,049
4,800
2,340
8,125
8,1252,3404,8009,04915,08426,5273,189
   > Long-term Assets 
70,257
115,636
164,267
233,813
237,085
198,408
112,316
112,316198,408237,085233,813164,267115,63670,257
       Property Plant Equipment 
49,825
78,815
88,333
98,727
84,579
77,921
73,041
73,04177,92184,57998,72788,33378,81549,825
       Intangible Assets 
20,432
36,517
75,402
75,614
90,702
78,213
16,559
16,55978,21390,70275,61475,40236,51720,432
       Other Assets 
0
304
532
1,363
889
828
1,913
1,9138288891,3635323040
> Total Liabilities 
127,181
121,423
100,191
102,170
85,422
100,887
117,156
117,156100,88785,422102,170100,191121,423127,181
   > Total Current Liabilities 
73,399
99,228
93,405
87,652
73,772
90,971
108,189
108,18990,97173,77287,65293,40599,22873,399
       Accounts payable 
0
12,967
14,191
6,643
930
1,054
3,135
3,1351,0549306,64314,19112,9670
       Other Current Liabilities 
68,479
75,804
46,459
39,432
39,957
36,055
46,487
46,48736,05539,95739,43246,45975,80468,479
   > Long-term Liabilities 
53,782
22,195
6,786
14,518
11,650
9,916
8,967
8,9679,91611,65014,5186,78622,19553,782
       Long term Debt Total 
0
0
0
1,587
443
1,182
0
01,1824431,587000
       Other Liabilities 
53,782
22,195
6,786
12,931
11,207
8,734
7,146
7,1468,73411,20712,9316,78622,19553,782
       Deferred Long Term Liability 
0
0
275
1,363
889
416
698
6984168891,36327500
> Total Stockholder Equity
272,359
596,961
3,427,412
3,324,217
2,981,650
2,729,072
2,539,886
2,539,8862,729,0722,981,6503,324,2173,427,412596,961272,359
   Common Stock
9
9
764
754
750
746
742
74274675075476499
   Retained Earnings -1,029,688-714,845-515,828-306,587-210,618-145,545-91,610
   Capital Surplus 
92,234
92,234
2,959,390
2,913,131
2,898,056
2,883,558
0
02,883,5582,898,0562,913,1312,959,39092,23492,234
   Treasury Stock00-4,5220000
   Other Stockholders Equity 
271,726
650,263
677,876
716,919
603,194
578,322
702,001
702,001578,322603,194716,919677,876650,263271,726



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue54,090
Cost of Revenue-78,782
Gross Profit-24,692-24,692
 
Operating Income (+$)
Gross Profit-24,692
Operating Expense-393,719
Operating Income-339,629-418,411
 
Operating Expense (+$)
Research Development267,102
Selling General Administrative32,414
Selling And Marketing Expenses0
Operating Expense393,719299,516
 
Net Interest Income (+$)
Interest Income44,162
Interest Expense-157
Other Finance Cost-0
Net Interest Income44,005
 
Pretax Income (+$)
Operating Income-339,629
Net Interest Income44,005
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-314,843-339,629
EBIT - interestExpense = -348,774
-314,843
-314,686
Interest Expense157
Earnings Before Interest and Taxes (EBIT)-348,617-314,686
Earnings Before Interest and Taxes (EBITDA)-284,495
 
After tax Income (+$)
Income Before Tax-314,843
Tax Provision-0
Net Income From Continuing Ops-314,843-314,843
Net Income-314,843
Net Income Applicable To Common Shares-314,843
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses4,639
Total Other Income/Expenses Net0-44,005
 

Technical Analysis of Ascletis
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Ascletis. The general trend of Ascletis is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Ascletis's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Ascletis Pharma Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.53 < 1.79 < 1.93.

The bearish price targets are: 1.24 > 1.24 > 1.24.

Tweet this
Ascletis Pharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Ascletis Pharma Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Ascletis Pharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Ascletis Pharma Inc. The current macd is -0.05322996.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Ascletis price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Ascletis. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Ascletis price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Ascletis Pharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartAscletis Pharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Ascletis Pharma Inc. The current adx is 14.54.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Ascletis shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Ascletis Pharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Ascletis Pharma Inc. The current sar is 1.778516.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Ascletis Pharma Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Ascletis Pharma Inc. The current rsi is 30.06. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Ascletis Pharma Inc Daily Relative Strength Index (RSI) ChartAscletis Pharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Ascletis Pharma Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Ascletis price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Ascletis Pharma Inc Daily Stochastic Oscillator ChartAscletis Pharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Ascletis Pharma Inc. The current cci is -220.75848303.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Ascletis Pharma Inc Daily Commodity Channel Index (CCI) ChartAscletis Pharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Ascletis Pharma Inc. The current cmo is -57.50517757.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Ascletis Pharma Inc Daily Chande Momentum Oscillator (CMO) ChartAscletis Pharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Ascletis Pharma Inc. The current willr is -100.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Ascletis Pharma Inc Daily Williams %R ChartAscletis Pharma Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Ascletis Pharma Inc.

Ascletis Pharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Ascletis Pharma Inc. The current atr is 0.08215192.

Ascletis Pharma Inc Daily Average True Range (ATR) ChartAscletis Pharma Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Ascletis Pharma Inc. The current obv is 33,690,928.

Ascletis Pharma Inc Daily On-Balance Volume (OBV) ChartAscletis Pharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Ascletis Pharma Inc. The current mfi is 26.93.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Ascletis Pharma Inc Daily Money Flow Index (MFI) ChartAscletis Pharma Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Ascletis Pharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-11-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-14MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-21RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-17CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-27ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Ascletis Pharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Ascletis Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5030.056
Ma 20Greater thanMa 501.614
Ma 50Greater thanMa 1001.671
Ma 100Greater thanMa 2001.682
OpenGreater thanClose1.500
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Ascletis with someone you think should read this too:
  • Are you bullish or bearish on Ascletis? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Ascletis? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Ascletis Pharma Inc

I send you an email if I find something interesting about Ascletis Pharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Ascletis Pharma Inc.

Receive notifications about Ascletis Pharma Inc in your mailbox!